PPAR{gamma} agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia

• Published in: Biochemical and biophysical research communications 2009-02, Vol.380 (1)
• Main Authors: Lee, Seong-Ryong, Chronic Disease Research Center and Institute for Medical Science, School of Medicine, Keimyung University, Taegu, Kim, Hahn-Young, Hong, Jung-Suk, Department of Emergency Medicine, Ulsan University Hospital, Ulsan, Baek, Won-Ki, Park, Jong-Wook, Department of Immunology, School of Medicine, Keimyung University, Taegu
• Format: Article
• Language: English
• Subjects: 60 APPLIED LIFE SCIENCES; BRAIN; INCUBATION; INHIBITION; ISCHEMIA; MICE
• ISSN: 0006-291X; 1090-2104
• DOI: 10.1016/j.bbrc.2008.12.181

Pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR{gamma}) agonist, has shown protective effects against ischemic insult in various tissues. Pioglitazone is also reported to reduce matrix metalloproteinase (MMP) activity. MMPs can remodel extracellular matrix components in many pathological conditions. The current study was designed to investigate whether the neuroprotection of pioglitazone is related to its MMP inhibition in focal cerebral ischemia. Mice were subjected to 90 min focal ischemia and reperfusion. In gel zymography, pioglitazone reduced the upregulation of active form of MMP-9 after ischemia. In in situ zymograms, pioglitazone also reduced the gelatinase activity induced by ischemia. After co-incubation with pioglitazone, in situ gelatinase activity was directly reduced. Pioglitazone reduced the infarct volume significantly compared with controls. These results demonstrate that pioglitazone may reduce MMP-9 activity and neuronal damage following focal ischemia. The reduction of MMP-9 activity may have a possible therapeutic effect for the management of brain injury after focal ischemia.